Миелопролиферативные новообразования. Василий Анатольевич Шуваев
(Bosutinibum) – описание вещества, инструкция… – РЛС. 2018 [cited 2018 29.04.2018]; Available from: https://www.rlsnet.ru/mnn_index_id_6602.htm.
47. Инструкция по медицинскому применению лекарственного препарата Айклусиг. [cited 2022 07.05.2022]; Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dcc203ed-3a4b-483b-b1be-9b5e94b76a17&t=.
48. Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase / F. Castagnetti, F. Pane, G. Rosti et al. // Frontiers in oncology. – 2021. – Vol. 11. – P. 642005–642005.
49. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial / J. E. Cortes, D. W. Kim, J. Pinilla-Ibarz et al. // Blood. – 2018. – Vol. 132, № 4. – P. 393–404.
50. ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML–CP) / T. P. Hughes, A. Hochhaus, G. Saglio et al. // ASH Annual Meeting Abstracts. – 2010. – Vol. 116, № 21. – P. 207-.
51. Hochhaus, A., Shah, N. P., Cortes, J. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML–CP): DASISION 3-year follow-up / A. Hochhaus, N. P. Shah, J. Cortes // Blood. – 2012. – Vol. 119, № 5. – P. 1123–1129.
52. Wei, G., Rafiyath, S., Liu, D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib / G. Wei, S. Rafiyath, D. Liu // Journal of Hematology & Oncology. – 2010. – Vol. 3, № 1. – P. 47.
53. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial / J. E. Cortes, C. Gambacorti-Passerini, M. W. Deininger et al. // J Clin Oncol. – 2018. – Vol. 36, № 3. – P. 231–237.
54. ENESTnd 5-Year Follow-Up: Continued Benefit of Frontline Nilotinib vs Imatinib in Patients With CML in Chronic Phase / T. Hughes, Le Coutre, P, Jootar et al. // Haematologica. – 2014. – Vol. 99, №Suppl.1. – P. Abstract S677.
55. Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML–CP): Long-Term Follow-Up (f/u) of ENESTnd / R. A. Larson, D-W. Kim, S. Issaragrisil et al. // Blood. – 2014. – Vol. 124, № 21. – P. 4541.
56. Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML–CP) Trial (DASISION, CA180–056) / J. Cortes, G. Saglio, M. Baccarani et al. // Blood. – 2014. – Vol. 124, № 21. – P. 152.
57. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) / E. Jabbour, H. M. Kantarjian, G. Saglio et al. // Blood. – 2013. – Vol. 123, № 4. – P. 494–500.
58. Expanding Nilotinib Access in Clinical Trials (ENACT) / F. E. Nicolini, A. Turkina, Z.-X. Shen et al. // Cancer. – 2012. – Vol. 118, № 1. – P. 118–126.
59. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy / A. Hochhaus, H. M. Kantarjian, M. Baccarani et al. // Blood. – 2007. – Vol. 109, № 6. – P. 2303–2309.
60. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML–CP) with resistance or intolerance to imatinib (START-C) / M. J. Mauro, M. Baccarani, F. Cervantes // Journal of Clinical Oncology. – 2008. – Vol. 26, № 15S (May 20 Supplement). – P. 7009.
61. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or – intolerant chronic myeloid leukemia in blast crisis / J. Cortes, P. Rousselot, D.-W. Kim et al. // Blood. – 2007. – Vol. 109, № 8. – P. 3207–3213.
62. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or – intolerant chronic myeloid leukemia in accelerated phase / F. Guilhot, J. Apperley, D.-W. Kim et al. // Blood. – 2007. – Vol. 109, № 10. – P. 4143–4150.
63. A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 'START-A' Study / F. Guilhot, J. F. Apperley, N. Shah et al. // ASH Annual Meeting Abstracts. – 2005. – Vol. 106, № 11. – P. 39.
64. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib / J. E. Cortes, H. M. Kantarjian, T. H. Brümmendorf et al. // Blood. – 2011. – Vol. 118, № 17. – P. 4567–4576.
65. Tefferi, A., Letendre, L. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia / A. Tefferi, L. Letendre // American Journal of Hematology. – 2011. – Vol. 86, № 7. – P. 610–611.
66. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors / P. Valent, E. Hadzijusufovic, G.-H. Schernthaner et al. // Blood. – 2014. – Vol. 125, № 6. – P. 901–906.
67. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia / A. Quintás-Cardama, X. Han, H. Kantarjian, J. Cortes // Blood. – 2009. – Vol. 114, № 2. – P. 261–263.
68. Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure / A. Quintás-Cardama, H. Kantarjian, S. O'Brien et al. // Journal of Clinical Oncology. – 2007. – Vol. 25, № 25. – P. 3908–3914.
69. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily / M.-T. Krauth, S. Herndlhofer, M-T. Schmook et al.// Haematologica. – 2011. – Vol. 96, № 1. – P. 163–166.
70. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial / J. E. Cortes, D.-W. Kim, J. Pinilla-Ibarz et al. // Blood. – 2018. – Vol. 132, № 4. – P. 393–404.
71. CML patients with T315I mutation: characteristics and outcomes of the treatment / J. Y. Vlasova, E. V. Morozova, M. V.Barabanshchikova et al.// Cellular Therapy and Transplantation. – 2018. – Vol. 7, № 3. – P. 130–132.
72. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation / A. Gratwohl, J. Hermans, J. M. Goldman et al. // The Lancet. – 1998. – Vol. 352, № 9134. – P. 1087–1092.
73. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia / L. Steegmann, M. Baccarani, Breccia M. et al. // Leukemia. – 2016. – Vol. 30, № 8. – P. 1648–1671.
74. Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: The EURO-SKI study / F.-X. Mahon, J. Richter, J. Guilhot et al.// Blood. – 2015. —, № 56th Annual Meeting and Exposition, San Francisco, CA December 6–9, 2014. – P. Abstract 151.
75. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial / F.-X. Mahon, D. Rea, J. Guilhot et al.// The Lancet Oncology. – 2010. – Vol. 11, № 11. – P. 1029–1035.
76. Mahon, F.-X. Discontinuation of tyrosine kinase therapy in CML / F.-X. Mahon // Annals of Hematology. – 2015. – Vol. 94, № 2. – P. 187–193.
77. Hughes,